Sugi Predict

Sugi Predict / Compounds / SCHEMBL4573137

SCHEMBL4573137

SCHEMBL4573137

CC(C)(C)OC(=O)N1CCN(c2nc(C(F)(F)F)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.46
▸ CTSS P25774 1/20 0.46
▸ CTSK P43235 1/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ MAPT P10636 5/20 0.45
▸ LMNA P02545 4/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ HDAC4 P56524 1/20 0.43
▸ CKS1B P61024 1/20 0.43
▸ SKP1 P63208 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ GBA1 P04062 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8114293 0.90 LMNA (0.55) CTSBCTSSCTSKKCNH2MAPT
SCHEMBL17541646 0.86 HRH3 (0.55) MAPTLMNAALDH1A1MAPK1HTT
SCHEMBL16836615 0.84 CKS1B (0.47) CTSBCTSSCTSKKCNH2MAPT
SCHEMBL18702207 0.83 NPC1 (0.50) CTSBCTSSCTSKKCNH2MAPT
SCHEMBL18711652 0.83 CTSB (0.49) CTSBCTSSCTSKKCNH2MAPT
SCHEMBL31518433 0.82 PDE4B (0.45) MAPTLMNAALDH1A1HDAC4GPR119
SCHEMBL2070545 0.82 GBA1 (0.47) KCNH2MAPTLMNAALDH1A1MAPK1
SCHEMBL31539296 0.82 MAPT (0.49) MAPTLMNAALDH1A1MAPK1HTT
SCHEMBL31518416 0.81 MAPT (0.44) MAPTLMNAALDH1A1MAPK1HTT
SCHEMBL19283721 0.81 CTSB (0.50) CTSBCTSSCTSKKCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398130-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2025-08-26 — — US disclosed
WO-2025085848-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-04-24 — — WO disclosed
WO-2025054132-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-03-13 — — WO disclosed
US-12187741-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2025-01-07 — — US disclosed
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2023-04-20 — — US disclosed
US-11591327-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2023-02-28 — — US disclosed
CN-109071526-B Acid addition salts of piperazine derivatives 阿森纽荣股份公司 2023-02-28 — — CN disclosed
US-20220411440-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-12-29 — — US disclosed
CN-107108601-B Glycosidase inhibitors 阿森纽荣股份公司 2021-08-20 — — CN disclosed
EP-3186243-B1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-21 — — EP disclosed
US-20190055233-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2019-02-21 — — US disclosed
US-20170298082-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2017-10-19 — — US disclosed
CN-107108601-A Glycosidase inhibitor 阿森纽荣股份公司 2017-08-29 — — CN disclosed
EP-3186243-A1 GLYCOSIDASE INHIBITORS Asceneuron SA (CH) 2017-07-05 — — EP disclosed
WO-2016030443-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2016-03-03 — — WO disclosed
CN-101374813-A Arylsulfonamide and sulfonyl compounds as PPAR modulators and methods of treating metabolic disorders KALYPSYS INC (US) 2009-02-25 — — CN disclosed
WO-2009001127-A1 CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS ASTRAZENECA AB (SE) 2008-12-31 — — WO disclosed
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 — — EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 — — WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055233-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES DNPEP, GAA, SLC30A5 CTSB 538/4885CTSS 411/4885CTSK 977/4885
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES DNPEP, GAA, SLC30A5 CTSB 538/4885CTSS 411/4885CTSK 977/4885
US-20220411440-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 CTSB 247/4885CTSS 245/4885CTSK 330/4885
US-11591327-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 CTSB 538/4885CTSS 411/4885CTSK 977/4885
US-12187741-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 CTSB 247/4885CTSS 245/4885CTSK 330/4885
US-20170298082-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 CTSB 247/4885CTSS 245/4885CTSK 330/4885
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD CTSB 1991/4885CTSS 1454/4885CTSK 2699/4885
US-12398130-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 CTSB 538/4885CTSS 411/4885CTSK 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.